SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - SAB Biotherapeutics, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $85 million to fund the development of its clinical-stage product candidate, SAB-142, targeting type 1 diabetes and other autoimmune diseases [1][2]. Group 1: Offering Details - The company is offering 19,324,677 shares of common stock at a price of $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 each, with gross proceeds expected to be around $85 million before expenses [1]. - Underwriters have a 30-day option to purchase an additional 3,311,688 shares on the same terms [1]. - The offering is expected to close on or about March 19, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the continued development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes [2]. Group 3: Company Overview - SAB Biotherapeutics is focused on developing human immunoglobulin G (hIgG) to treat autoimmune disorders, utilizing advanced genetic engineering and proprietary technology [6]. - The lead candidate, SAB-142, aims to modify the treatment paradigm for type 1 diabetes by delaying onset and potentially preventing disease progression in Stage 3 patients [6]. - SAB-142 is currently in a registrational Phase 2b clinical trial named SAFEGUARD [6].